Streetbeat News

CMPGY

Compass Group Plc

http://www.compass-group.com/

CEO

Dominic Blakemore

Open

33.70

Mkt cap

57B

Volume

700

High

33.75

P/E Ratio

41.07

52-wk high

35.91

Low

33.68

Div yield

0.02

52-wk low

26.55

Circus SE has appointed Jürgen Thamm, former Regional Director at Compass Group, to its Advisory Board. Thamm's expertise in food service and strategic growth will support Circus' mission to automate food service using AI and robotics.

Portfolio Pulse from

December 18, 2024 | 7:30 am

Compass Minerals reported its fiscal fourth-quarter and full-year 2024 results, highlighting a strategic shift back to its core Salt and Plant Nutrition businesses.

Portfolio Pulse from

December 16, 2024 | 9:45 pm

Veeva Systems has announced growing momentum for its Veeva Compass Patient, a tool that aids biopharmaceutical companies in improving commercialization by leveraging anonymous patient data.

Portfolio Pulse from

December 12, 2024 | 12:15 pm

Compass Group is expected to exceed sales and margin expectations for fiscal 2025 due to growth momentum, portfolio restructuring, and industry trends. Positive surprises in financial performance could act as catalysts for stock re-rating.

Portfolio Pulse from

December 10, 2024 | 3:45 pm

Compass (COMP) is highlighted as a stock with strong recent momentum and is considered a bargain, making it an attractive option for investors seeking value and growth.

Portfolio Pulse from

December 10, 2024 | 3:00 pm

Compass Therapeutics has appointed Barry Shin as their new Chief Financial Officer. Shin brings over 20 years of experience in the biopharmaceutical industry, which could positively impact the company's financial strategies and operations.

Portfolio Pulse from

December 10, 2024 | 1:15 pm

Compass Minerals will release its Q4 and fiscal 2024 results on December 16, 2024, followed by a conference call on December 17, 2024, led by CEO Edward C. Dowling Jr. and CFO Jeffrey Cathey.

Portfolio Pulse from

December 09, 2024 | 11:00 pm

Compass Diversified (NYSE: CODI) will host an investor day on January 16, 2025, in New York City, providing insights into its business operations and future plans.

Portfolio Pulse from

December 09, 2024 | 9:30 pm

Compass Therapeutics' CTX-009 shows promise in biliary tract cancer with a 37.5% response rate in phase 2 trials. A pivotal phase 2/3 readout is expected in Q1 2025. The company is financially stable with sufficient cash to last through 2025. However, risks include a non-standard comparator in trials and historically low success rates for similar therapies.

Portfolio Pulse from

December 09, 2024 | 6:15 pm

Compass, Inc. (COMP) is highlighted as a potential top stock pick for momentum investors, suggesting it may have strong short-term growth potential.

Portfolio Pulse from

December 05, 2024 | 6:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.